Anticipating and Identifying Collateral Damage in Genome Editing
| dc.contributor.author | Burgio, Gaetan | |
| dc.contributor.author | Teboul, Lydia | |
| dc.date.accessioned | 2022-10-04T03:25:03Z | |
| dc.date.available | 2022-10-04T03:25:03Z | |
| dc.date.issued | 2020 | |
| dc.date.updated | 2021-11-28T07:21:02Z | |
| dc.description.abstract | Genome editing has a transformative potential in healthcare or to improve crops or livestock. However, the use of Cas9 or other nucleases can yield unpredictable events at the target site or off target. To overcome these challenge, it is critical to understand and accurately predict the whole range of possible editing outcomes. The key to success is to combine molecular assays to evaluate the sequence changes at the target site and to quantify the number of copies of segments deleted/inserted across the genome. For all applications, thorough evaluation of these outcomes is essential to identify all collateral damage from nuclease activity and for a real appraisal of the benefits and risks associated with applying this technology. | en_AU |
| dc.description.sponsorship | L.T. was supported by Medical Research Council in the UK (grant A410) and the National Institute for Health in the USA (Grant U42OD011174). G.B. was supported by the National collaborative Research Infrastructure (NCRIS) via the Australian Phenomics Network, the National Health and Medical Research Council (NHMRC) of Australia (Grant APP1143008), the Australian Research Council (ARC) (Grant DP180101494), and the National Natural Science Foundation of China (NSFC) (Grant 81772214). | en_AU |
| dc.format.mimetype | application/pdf | en_AU |
| dc.identifier.issn | 0168-9525 | en_AU |
| dc.identifier.uri | http://hdl.handle.net/1885/274269 | |
| dc.language.iso | en_AU | en_AU |
| dc.provenance | This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | en_AU |
| dc.publisher | Elsevier | en_AU |
| dc.relation | http://purl.org/au-research/grants/nhmrc/1143008 | en_AU |
| dc.relation | http://purl.org/au-research/grants/arc/DP180101494 | en_AU |
| dc.rights | © 2020 Elsevier Ltd. | en_AU |
| dc.rights.license | CC BY-NC-ND license | en_AU |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_AU |
| dc.source | Trends in Genetics | en_AU |
| dc.title | Anticipating and Identifying Collateral Damage in Genome Editing | en_AU |
| dc.type | Journal article | en_AU |
| dcterms.accessRights | Open Access | en_AU |
| local.bibliographicCitation.issue | 12 | en_AU |
| local.bibliographicCitation.lastpage | 914 | en_AU |
| local.bibliographicCitation.startpage | 905 | en_AU |
| local.contributor.affiliation | Burgio, Gaetan, College of Health and Medicine, ANU | en_AU |
| local.contributor.affiliation | Teboul, Lydia , Medical Research Council Harwell Institute, Harwell Campus | en_AU |
| local.contributor.authoruid | Burgio, Gaetan, u5727247 | en_AU |
| local.description.notes | Imported from ARIES | en_AU |
| local.identifier.absfor | 320603 - Medical molecular engineering of nucleic acids and proteins | en_AU |
| local.identifier.absfor | 320601 - Gene and molecular therapy | en_AU |
| local.identifier.absfor | 310113 - Synthetic biology | en_AU |
| local.identifier.absseo | 240803 - Human pharmaceutical treatments | en_AU |
| local.identifier.absseo | 280103 - Expanding knowledge in the biomedical and clinical sciences | en_AU |
| local.identifier.absseo | 200105 - Treatment of human diseases and conditions | en_AU |
| local.identifier.ariespublication | a383154xPUB14943 | en_AU |
| local.identifier.citationvolume | 36 | en_AU |
| local.identifier.doi | 10.1016/j.tig.2020.09.011 | en_AU |
| local.publisher.url | https://www.elsevier.com/en-au | en_AU |
| local.type.status | Published Version | en_AU |
Downloads
Original bundle
1 - 1 of 1
Loading...
- Name:
- 1-s2.0-S016895252030247X-main.pdf
- Size:
- 877.88 KB
- Format:
- Adobe Portable Document Format
- Description: